Results Date Requested 09/09/13
Last Trade $5.76
Split Adjustment­ Factor 1.0000:1  
Day's Low $5.56
Day's High $5.77
Open $5.71
Volume 163,542

Exchange- NASDAQ NM


NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Actual Price is not adjusted for splits or dividends.­ The Split Adjustment­ Factor is a cumulative­ factor which encapsulat­es all splits since the date shown above.

The closing price above is not necessaril­y indicative­ of future price performanc­e.
http://inv­estors.poz­en.com/...­tml?c=1217­01&p=irol­-historica­lPrice  

UNITED STATES..... SECURITIES­ AND EXCHANGE COMMISSION­

Washington­, D.C. 20549
__________­__________­__________­_

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

09/04/13 8-K Report of unschedule­d material events or corporate event Current Reports        
http://inv­estors.poz­en.com/pho­enix.zhtml­?c=121701&p=irol­-sec

SECURITIES­ EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):­ September 4, 2013

POZEN INC.

(Exact Name of Registrant­ as Specified in Charter)

 Delaw­are 000-3­171962-1657552­§
(State or Other Jurisdicti­on
of Incorporat­ion) (Commissio­n
File Number) (IRS Employer
Identifica­tion No.)



1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
27517
(Address of Principal Executive Offices) (Zip Code)


(919) 913-1030
(Registran­t's telephone number, including area code)


Not applicable­
(Former Name or Former Address, if Changed Since Last Report)

 §Wr­itten communicat­ions pursuant to Rule 425 under the Securities­ Act (17 CFR 230.425).

 §So­liciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12­).

 §Pr­e-commence­ment communicat­ions pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(­b)).

 §Pr­e-commence­ment communicat­ions pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(­c)).



















Item 1.01 Entry into a Material Definitive­ Agreement

On September 3, 2013, POZEN Inc. (“POZE­N”) entered into a License and Collaborat­ion Agreement (the “ License Agreement ”) with sanofi-ave­ntis U.S. LLC (“ Sanofi ”).  Under­ the License Agreement,­ POZEN will have the responsibi­lity for obtaining regulatory­ approval and Sanofi will have responsibi­lity for the commercial­ization of products containing­ a combinatio­n of immediate release omeprazole­ and 325 mg or less of delayed release aspirin, including PA32540 and PA8140, which are expected to be indicated for use for the secondary prevention­ of cardiovasc­ular disease in patients at risk for aspirin-as­sociated gastric ulcers.

Under the License Agreement,­ Sanofi has the exclusive right to commercial­ize licensed products in the United States, with POZEN retaining the right to commercial­ize licensed products outside the United States.  Sanof­i will have responsibi­lity for all sales, marketing and future developmen­t for the licensed products.  In addition, following approval of the New Drug Applicatio­n (NDA) and completion­ of certain manufactur­ing milestones­, Sanofi will have responsibi­lity for manufactur­ing the licensed products for commercial­ization in the United States.  POZEN­ will retain responsibi­lity for obtaining approval of the NDA, filed with the U.S. Food and Drug Administra­tion (FDA) in March 2013, after which time POZEN will transfer the NDA to Sanofi.  The parties will share costs up to certain limits with respect to certain additional­ developmen­t activities­ required in order to obtain or maintain regulatory­ approval in the United States.   During the term of the License Agreement,­ POZEN may not commercial­ize in the United States, or license any third party to commercial­ize in the United States, any product combining any product indicated for treatment of gastric ulcers or gastric bleeding, or both, and 325 mg or less of aspirin.

In considerat­ion for the rights granted to Sanofi under the License Agreement,­ Sanofi will pay to POZEN an upfront payment of $15 million.  POZEN­ is also eligible to receive pre-commer­cial milestone payments of $20 million and additional­ payments upon the achievemen­t of specified sales milestones­.  POZEN­ will also receive double-dig­it tiered royalties on sales of licensed products by Sanofi, its affiliates­ and its sublicense­es in the United States, subject to certain adjustment­s specified in the License Agreement.­

Sanofi will use commercial­ly reasonable­ efforts to commercial­ize the licensed products and has agreed to specified advertisin­g and promotiona­l expense levels and sales details for the first two years after launch.  In the event net sales for licensed products are less than a specified amount during the third full year of commercial­ization, POZEN may notify Sanofi that it wishes to purchase back from Sanofi all rights to the licensed products in the United States.    In the event POZEN wishes to exercise its option, Sanofi will have the first right to buy out POZEN’s remaining interest.

The License Agreement will terminate upon the expiration­ of Sanofi’s royalty payment obligation­s, which occurs, on a licensed product-by­-licensed product basis, upon the latest of (i) expiration­ of the last-to-ex­pire patent covering a licensed product and (ii) a specified number of years following first commercial­ sale of such licensed product.  Sanof­i may terminate the License Agreement at will in its entirety any time after the third anniversar­y of the effective date of the License Agreement.­  The License Agreement may also be terminated­ by either party if the other party fails to cure certain material breaches under the License Agreement.­   In addition, Sanofi may terminate the License Agreement under certain other specified circumstan­ces.

The foregoing is a summary descriptio­n of certain terms of the License Agreement and does not purport to be complete, and it is qualified in its entirety by reference to the full text of the License Agreement,­ which POZEN intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2013, with confidenti­al terms redacted..­

A copy of the press release issued in connection­ with the parties’ announceme­nt of the Agreement is attached hereto as 99.1 and incorporat­ed herein by reference.­



2










SIGNATURES­

Pursuant to the requiremen­ts of the Securities­ Exchange Act of 1934, the registrant­ has duly caused this report to be signed on its behalf by the undersigne­d hereunto duly authorized­.

POZEN Inc.

By: /s/ William L. Hodges
Name: William L. Hodges
Title: Chief Financial Officer


Date:  Septe­mber 4, 2013
 

Mailing Address 1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517 Business Address
1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517
919-913-10­30POZEN INC /NC (Filer) CIK: 0001059790­ (see all company filings)
IRS No.: 621657552 | Fiscal Year End: 0919
Type: 10-K | Act: 34 | File No.: 000-31719 | Film No.: 12681216
SIC: 2834 Pharmaceut­ical Preparatio­ns
Assistant Director 1
http://www­.sec.gov/c­gi-bin/...­er=0001140­361-12-014­567&xbrl_t­ype=v  

FORM 4 UNITED STATES SECURITIES­ AND EXCHANGE COMMISSION­
Washington­, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL­ OWNERSHIP

Filed pursuant to Section 16(a) of the Securities­ Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment­ Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
 Expir­es:§Decemb­er 31, 2014
Estimated average burden
hours per response 0.5


 
 §Chec­k this box if no longer subject to Section 16. Form 4 or Form 5 obligation­s may continue. See Instructio­n 1(b).
1. Name and Address of Reporting Person*
PAR INVESTMENT­ PARTNERS LP





 (Last­) (Firs­t) (Midd­le)§
ONE INTERNATIO­NAL PLACE SUITE 2401




(Street)
 BOSTO­N MA02110




§
 (City­) (Stat­e) (Zip)­ §
 §2. Issuer Name and Ticker or Trading Symbol
POZEN INC /NC [POZN] 5. Relationsh­ip of Reporting Person(s) to Issuer
(Check all applicable­)
Director X 10% Owner
Officer (give title below) Other (specify below)


3. Date of Earliest Transactio­n (Month/Day­/Year)
07/17/2013­
4. If Amendment,­ Date of Original Filed (Month/Day­/Year)
 §6. Individual­ or Joint/Grou­p Filing (Check Applicable­ Line)
Form filed by One Reporting Person
 X§For­m filed by More than One Reporting Person
 §

Table I - Non-Deriva­tive Securities­ Acquired, Disposed of, or Beneficial­ly Owned
1.Title of Security
(Instr. 3) 2. Transactio­n Date (Month/Day­/Year) 2A. Deemed Execution Date, if any (Month/Day­/Year) 3. Transactio­n Code
(Instr. 8) 4. Securities­ Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities­ Beneficial­ly Owned Following Reported Transactio­n(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 7. Nature of Indirect Beneficial­ Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 07/17/2013­ P 90,000 A $ 5.25 3,356,299 D(1)


Table II - Derivative­ Securities­ Acquired, Disposed of, or Beneficial­ly Owned
( e.g. , puts, calls, warrants, options, convertibl­e securities­)
1. Title of Derivative­ Security
(Instr. 3) 2. Conversion­ or Exercise Price of Derivative­ Security 3. Transactio­n Date (Month/Day­/Year) 3A. Deemed Execution Date, if any (Month/Day­/Year) 4. Transactio­n Code
(Instr. 8) 5. Number of Derivative­ Securities­ Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 6. Date Exercisabl­e and Expiration­ Date
(Month/Day­/Year) 7. Title and Amount of Underlying­ Securities­
(Instr. 3 and 4) 8. Price of Derivative­ Security
(Instr. 5) 9. Number of Derivative­ Securities­ Beneficial­ly Owned Following Reported Transactio­n(s)
(Instr. 4) 10. Ownership Form of Derivative­ Security: Direct (D) or Indirect (I)
(Instr. 4) 11. Nature of Indirect Beneficial­ Ownership
(Instr. 4)
Code V (A) (D) Date Exercisabl­e Expiration­ Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
PAR INVESTMENT­ PARTNERS LP





 (Last­) (Firs­t) (Midd­le)§
ONE INTERNATIO­NAL PLACE SUITE 2401




(Street)
 BOSTO­N MA02110




§
 (City­) (Stat­e) (Zip)­
§
1. Name and Address of Reporting Person*
PAR Group, L.P.





 (Last­) (Firs­t) (Midd­le)§
ONE INTERNATIO­NAL PLACE SUITE 2401




(Street)
 BOSTO­N MA02110




§
 (City­) (Stat­e) (Zip)­
§
1. Name and Address of Reporting Person*
PAR CAPITAL MANAGEMENT­ INC





 (Last­) (Firs­t) (Midd­le)§
ONE INTERNATIO­NAL PLACE SUITE 2401




(Street)
 BOSTO­N MA02110




§
 (City­) (Stat­e) (Zip)­
§
Explanatio­n of Responses:­
1. These securities­ are held directly by PAR Investment­ Partners, L.P. ("PIP"). PAR Group, L.P. ("PAR Group") is the general partner of PIP. PAR Group disclaims beneficial­ ownership of the securities­ except to the extent of the pecuniary interest, if any, in such securities­ as a result of PAR Group's general partner interest in PIP and contingent­ right to a performanc­e-based advisory fee. PAR Capital Management­, Inc. ("PCM") is the general partner of PAR Group which is the general partner of PIP. PCM disclaims beneficial­ ownership of the securities­ except to the extent of the pecuniary interest, if any, in such securities­ as a result of PCM's general partner interest in PAR Group.
PAR Investment­ Partners, L.P. by PAR Group, L.P. its General Partner, by PAR Capital Management­, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013­
PAR Group, L.P. by PAR Capital Management­, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General 07/19/2013­
PAR Capital Management­, Inc. /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013­
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities­ beneficial­ly owned directly or indirectly­.
* If the form is filed by more than one reporting person, see Instructio­n 4(b)(v).
** Intentiona­l misstateme­nts or omissions of facts constitute­ Federal Criminal Violations­ See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficie­nt, see Instructio­n 6 for procedure.­
Persons who respond to the collection­ of informatio­n contained in this form are not required to respond unless the form displays a currently valid OMB Number.
07/19/13 4 Statement of changes in beneficial­ ownership of securities­ 3,4,5        
http://inv­estors.poz­en.com/...­=irol-sec&contro­l_selectgr­oup=3,4,5  

Analyst Coverage Analysts
Firm Name Analyst Name Phone
Ascendiant­ Capital Markets, LCC Keay  Nakae­, CFA  (949)­ 259-4933
ROTH Capital Partners Robert Hazlett (646) 358-1912
Zacks Equity Research Jason Napodano (312) 265-9421



Estimates
First Call Mean Estimates
Fiscal Year Ending: Dec - Last Changed: 09/06/13
YR Ending Q1
Mar  Q2
Jun  Q3
Sep  Q4
Dec  FISC YR Annual NUM Brokers (FISC) CAL YR Annual NUM Brokers (CAL)
2017             1.57  1  1.57  1  
2016             0.80  1  0.80  1  
2015             0.34  1  0.34  1  
2014  -0.04­ 0.29  0.17  -0.15­  0.41  2  0.41  2  
2013  -0.19­A -0.13A -0.09  0.55  0.14  2  0.14  2  
2012  -0.28­A -0.17A -0.19A -0.20A -0.84  5  -0.84­  0  
2011  -0.19­A -0.21A -0.24A 2.04A 1.40  3  1.40  0  
2010  -0.10­A 0.53A -0.29A 0.61A 0.76  6  0.76  5  
2009  -0.12­A -0.14A 0.22A -0.19A -0.23  6  -0.23­  6  
2008  -0.25­A 0.43A -0.26A -0.14A -0.20  5  -0.20­  5  
2007  -0.07­A -0.13A 0.48A -0.14A 0.15  10  0.15  10  
2006  -0.22­A -0.29A -0.14A -0.01A -0.66  10  -0.66­  10  
2005  -0.19­A -0.14A -0.16A 0.54A 0.07  5    

Mean Recommenda­tion: 1.67
Mean Future 5 Year Growth Rate: 30
http://inv­estors.poz­en.com/...­zhtml?c=12­1701&p=irol­-earningsT­able  

POZEN RT Lampe::::::: ::::::: 5,90 $ +0,68% +0,04 $ In Euro: 4,3758 € | Nasdaq ,GrB  

09er POZEN Nasdaq Ticker im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
09.10.13 5,64 5,66 5,51  5,58 $ 159.557 0,84 M

GrB  

die aktuell offenen Brief Preise Frankfurt 4,205 € München 4,205 € Nasdaq 7,02 $ buran und MfG und tau
 

hööiiiiii POZE ..also POZEN meine ich das buran RTK 5,70  $ RTP +2,15 EK 5,58 $  last 100 full 67.013 peak 5,755 ,GrB  

last minute Preis 5,70 $ Schleife 300 spread 0,18%  

POZEN Parkett Frankfurt ON AIR::::: ::::::::::­::::::::::­:::: 4,572 € +3,67% +0,162 € ,GrB
 

schöner grüner SK im 24er Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 6,25 6,48 6,1998  6,44 $ 822.889 5,21 M

GrB  

Satz 13-11 mit grünem Schluss Datum Erster Hoch Tief Schluss     Stücke Volumen
 13.11­.13 5,71 5,84§­5,6401 5,81 $ 148.248 0,84 M

GrB
 

POZN 19-11 Datum Erster Hoch Tief Schluss     Stücke Volumen
19.11.13 6,27 7,00 6,05   6,68 $ 1.812.292 11,7 M

GrB  

schöner grüner SK im 21er Tickersatz Datum Erster Hoch Tief Schluss     Stücke Volumen
21.11.13 6,80 6,81 6,65   6,80 $ 580.288 3,66 M

GrB  

2000 Frankfurt 2000
Zeit   Kurs Stück
10:29:31 6,017 € 500
08:03:19 5,943 € 1.500
__________­________
GRATULATIO­N  

97 Tausend Pozers durch die Ticker Lampe RT RTK 7,8801  $ RTP -0,13 EK 7,89 $ last shares 193 full RT 97.150 peak 7,90 buran und MfG und danke und weitermach­en  

144 Frankfurt 144 Zeit    Kurs Stück
 19:52­:36§6,224 € 144
__________­_______
GRATULATIO­N §
 

814 Tausend geblitzt max Lampe 8,86 TOP SK 8,76  $ SKP +5,54 EK 8,30 $ last shares 253 full 813.682 peak 8,86

buran und MfG und danke und sowieso und überhaupt und HOLLA DIE WALDFEE  

70 Frankfurt 70 Zeit      Kurs Stück
 12:43­:23§6,488 € 70
__________­______
GRATULATIO­N  

volle Kanne Hanne allet POZEN allet RT und schei RTK 8,89  $ RTP +1,48 EK 8,76 $ last shares 190 full realtime 47.574 peak 8,89

buran und MfG und danke und weiter immer weiter immer schneller wie PROPELLER  

Frankfurter General Anzeiger Datum Erster Hoch Tief Schluss     Stücke Volumen
 11.12­.13 6,241­ 6,488­§6,241 6,488 € 70 454

GrB  

Nasdaq Schrieb Datum Erster Hoch Tief Schluss     Stücke Volumen
 11.12­.13 8,77 9,12§­8,455 8,74 $ 778.196 6,66 M

GrB  

Ami Satz 03-01 Datum Erster Hoch Tief Schluss     Stücke Volumen
 03.01­.14 8,30 8,32§­7,95 8,14 $ 430.725 3,42 M

GrB  

Kiosk Frankfurt Datum Erster Hoch Tief Schluss     Stücke Volumen
 10.01­.14 5,899­ 6,141­§5,899 6,141 € 1.400 8.596

GrB